“…Currently, there are no commercial vaccines available against most of these diseases (Pedrique et al., 2013, Hotez et al., 2016), diagnostic methods frequently suffer from insufficient specificity and sensitivity (Utzinger et al., 2012, Assefa et al., 2014), and treatments are often not highly effective and/or are toxic (Castro et al., 2006, Witschel et al., 2012, Molina et al., 2015). In addition, often the small numbers of drugs (or drug classes) frequently used, limited use of combination drug therapies and the implementation of mass drug administration programs bear the risk of drug resistance emerging in some groups of target pathogens (Humphries et al., 2012, Witschel et al., 2012, Webster et al., 2014). Therefore, the development of new drugs is crucial to ensure effective and sustained treatment and control into the future.…”